Wall Street Zen Upgrades argenex (NASDAQ:ARGX) to Buy

argenex (NASDAQ:ARGX) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research note on Wednesday, January 14th. Wells Fargo & Company decreased their price target on argenex from $1,317.00 to $1,247.00 and set an “overweight” rating on the stock in a report on Friday. Citigroup dropped their price objective on argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Finally, Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and an average target price of $999.22.

argenex Price Performance

ARGX stock opened at $766.92 on Friday. The business has a fifty day moving average price of $826.36 and a 200 day moving average price of $813.13. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The stock has a market capitalization of $47.46 billion, a price-to-earnings ratio of 39.29, a P/E/G ratio of 1.16 and a beta of 0.38.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, February 26th. The company reported $8.02 EPS for the quarter, topping the consensus estimate of $6.05 by $1.97. argenex had a return on equity of 38.51% and a net margin of 30.42%.The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. On average, equities analysts expect that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in argenex by 91.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock worth $6,511,000 after acquiring an additional 4,217 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in shares of argenex by 21.3% in the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after acquiring an additional 645 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of argenex by 14.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock worth $162,160,000 after purchasing an additional 26,343 shares during the period. Alta Wealth Advisors LLC bought a new position in shares of argenex during the 3rd quarter valued at about $623,000. Finally, Fiera Capital Corp grew its position in shares of argenex by 12.1% in the 3rd quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock valued at $131,030,000 after purchasing an additional 19,180 shares during the period. Institutional investors own 60.32% of the company’s stock.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.